Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHARMACY PHARMACEUTICAL CO., LTD.

創美藥業股份有限公司 (A joint stock limited liability company established in the People's Republic of China) (Stock Code: 2289)

NOTICE OF THE 2022 SECOND EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN that an extraordinary general meeting (the "**EGM**") of Charmacy Pharmaceutical Co., Ltd. (the "**Company**") will be held at the conference room, on 2nd floor, No. 33, Song Liyu Street, Dongchong District, Guangzhou City, Guangdong Province, the People's Republic of China (the "**PRC**") at 3:00 p.m. on 7 July 2022 for the purpose of considering, and if thought fit, passing (with or without amendments) the following resolutions:

As Ordinary Resolutions

- 1. to consider and, if thought fit, approve the appointment of Ms. Zhang Hanzi as an executive director of the Company (the "**Director(s)**");
- 2. to consider and, if thought fit, approve the appointment of Ms. Fu Zheng as a non-executive Director;

As Special Resolution

3. to consider and, if thought fit, approve the proposed amendments to the articles of association of the Company (the "Articles of Association") (details of which are set out in the circular of the Company dated 21 June 2022) (please see Appendix 1), and that any Director be and is hereby authorised to modify the wordings of such amendments as appropriate (such amendments will not be required to be approved by the shareholders of the Company) and execute all such documents and/or do all such acts as the Directors may, in their absolute discretion, deem necessary or expedient and in the interest of the Company in order to deal with other related issues arising from the amendments to the Articles of Association.

For and on behalf of the Board Charmacy Pharmaceutical Co., Ltd. Yao Chuanglong Chairman

Shantou, the PRC, 21 June 2022

Notes:

1. All resolutions at the meeting will be taken by poll pursuant to the Listing Rules. The results of the poll will be published on the websites of The Stock Exchange of Hong Kong Limited and the Company in accordance with the Listing Rules.

2. The register of members of the Company will be closed from Friday, 1 July 2022 to Thursday, 7 July 2022 (both days inclusive), during which period no transfer of Shares can be registered. In order to be qualified to attend and vote at the EGM, all transfer documents accompanied by the relevant share certificate(s) must be lodged with the Company's H shares registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17 Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong (for holders of H shares of the Company) or the headquarters in the PRC of the Company at No. 235, Song Shan North Road, Longhu District, Shantou City, Guangdong Province, the PRC (for holders of domestic shares of the Company) for registration not later than 4:30 p.m. on Thursday, 30 June 2022.

3. Shareholders who are entitled to attend and vote at the EGM may appoint one or more proxies to attend and vote on their behalves. A proxy need not be a shareholder of the Company.

4. In order to be valid, the proxy form for the EGM must be deposited by hand or post, for holders of H shares of the Company, to the H share registrar of the Company, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong and, for holders of domestic shares of the Company, to the headquarters in the PRC of the Company at No. 235, Song Shan North Road, Longhu District, Shantou City, Guangdong Province, the PRC not less than 24 hours (not later than 3 p.m. on Wednesday, 6 July 2022) before the time for holding the EGM (or any adjournment thereof) for taking the poll. If the proxy form is signed by a person under a power of attorney or other authority, a notarial copy of that power of attorney or authority shall be deposited at the same time as mentioned in the proxy form. Completion and return of the proxy form will not preclude shareholders from attending and voting in person at the EGM or any adjourned meetings should they so wish.

If the proxy is a legal person, its legal representative or any representative authorised by a resolution of its board of directors or by other governing body shall attend the above meeting of the Company on its behalf. If the shareholder is a recognised clearing house (or its proxy) defined by the Hong Kong relevant Ordinance from time to time, the shareholder may authorise one or more persons it considers appropriate as its representative(s) at the above meeting; however, if more than one person are authorised, the power of attorney shall contain the number and class of shares for which such persons are authorised, and shall be signed by an authorised personnel of the recognised clearing house. The person(s) so authorised can represent the recognised clearing house (or its proxy)

to attend the meeting and exercise its right, as if the persons are the Company's individual shareholders, and shall not be required to produce evidence of shareholding, the notarised power of attorney and/or further evidence to prove that he/ she/they have been duly authorised.

A vote provided in according to the instruments in such proxy forms shall be valid, notwithstanding the previous death or loss of capacity of the appointer or the revocation of the proxy or of the authority under which the proxy was executed, or the shares are transferred, provided that no notice in writing of such matters shall have been received by the Company prior to the above meeting.

5. Shareholders or their proxies shall provide their identity documents when attending the EGM.

6. In case of joint holders of any share, only the person whose name is at the first place on the register of shareholders has the rights to receive the certificate of relevant shares and notice from the Company and to attend or exercise all of the votes relating to the shares.

As at the date of this notice, the executive Directors are Mr. Yao Chuanglong and Ms. Zheng Yuyan; the non-executive Directors are Mr. Li Weisheng and Mr.Yan Jingbin; and the independent non-executive Directors are Mr. Wan Chi Wai Anthony, Mr. Zhou Tao and Mr. Guan Jian (also known as Guan Suzhe).

APPENDIX 1

The special resolution on the amendment to the Articles of Association, details of which are set out as follows:

Article 10.1

Before Amendments	After Amendments
	(showing changes to the existing Articles of Association)
"The Company shall establish a board, which shall be	"The Company shall establish a board, which shall be
accountable to and report to the general meeting. The Board	accountable to and report to the general meeting. The Board
shall consist of seven directors, of which the external	shall consist of seven <i><u>nine</u></i> directors, of which the external
directors (hereinafter referred to directors who do not hold	directors (hereinafter referred to directors who do not hold
any office within the Company) shall represent not less than	any office within the Company) shall represent not less than
50 percent of the members of the Board of Directors.	50 percent of the members of the Board of Directors.
Independent non-executive directors (hereinafter referred to	Independent non-executive directors (hereinafter referred to
directors who are independent to the shareholders and do	directors who are independent to the shareholders and do
not hold any office within the Company) shall represent at	not hold any office within the Company) shall represent at
least one-third of the members of the Board of Directors.	least one-third of the members of the Board of Directors.
The Board of Directors shall have one chairman and may	The Board of Directors shall have one chairman and may
have one vice chairman."	have one vice chairman."